Description:
This is an international, multi-center, randomized, double-blinded, placebo-controlled
clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an
adjuvant treatment in patients with hormone receptor-positive, HER2-negative, intermediate
risk breast cancer.
Title
- Brief Title: Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
- Official Title: A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, Intermediate Risk Early Breast Cancer
Clinical Trial IDs
- ORG STUDY ID:
CLEE011H2301
- NCT ID:
NCT03081234
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Ribociclib | LEE011 | Ribociclib + adjuvant endocrine therapy |
Placebo | | Placebo + adjuvant endocrine therapy |
Adjuvant endocrine therapy | | Placebo + adjuvant endocrine therapy |
Purpose
This is an international, multi-center, randomized, double-blinded, placebo-controlled
clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an
adjuvant treatment in patients with hormone receptor-positive, HER2-negative, intermediate
risk breast cancer.
Detailed Description
While adjuvant endocrine therapy (ET) is effective in reducing risk of recurrence in patients
with hormone receptor (HR)-positive early breast cancer (EBC), recurrences are still common,
especially in patients with unfavorable clinical, pathological and/or molecular features.
Ribociclib, a CDK4/6 inhibitor, demonstrated clinical efficacy with tolerable toxicity when
added to ET in patients with HR-positive, HER2-negative advanced breast cancer. The purpose
of this study is to evaluate the effect of addition of ribociclib to standard adjuvant ET on
invasive disease-free survival in patients with HR+, HER2- intermediate-risk EBC.
Trial Arms
Name | Type | Description | Interventions |
---|
Ribociclib + adjuvant endocrine therapy | Experimental | Ribociclib in combination with standard adjuvant endocrine therapy | - Ribociclib
- Adjuvant endocrine therapy
|
Placebo + adjuvant endocrine therapy | Active Comparator | Placebo in combination with standard adjuvant endocrine therapy | - Placebo
- Adjuvant endocrine therapy
|
Eligibility Criteria
Key Inclusion Criteria:
- Histologically confirmed unilateral primary invasive adenocarcinoma of the breast
- Estrogen receptor-positive and/or progesterone receptor-positive, HER2-negative breast
cancer
- Patient is after surgical resection of the tumor where tumor was removed completely
with surgical specimen microscopic margins free from tumor and with available archival
tumor tissue from the surgical specimen
- Patient who have AJCC 8th edition Prognostic Stage Group II
- Patient has completed adjuvant radiotherapy (if indicated) according to the
institutional guidelines prior to screening
- Patient may already have initiated adjuvant endocrine therapy (ET) at the time of
randomization, but randomization must take place within 52 weeks of date of initial
histological diagnosis of breast cancer and within 12 weeks of initiating ET
- ECOG Performance Status 0 or 1
- Adequate bone marrow and organ function
- Sodium, potassium, phosphorus, magnesium and total calcium laboratory values within
normal limits
- QTcF interval < 450 msec and mean resting heart rate 50-90 bpm
Key Exclusion Criteria:
- Prior neoadjuvant therapy (endocrine therapy or chemotherapy) or CDK4/6 inhibitor
- Prior treatment with tamoxifen, raloxifen or aromatase inhibitors for reduction in
risk (chemoprevention) of breast cancer and/or treatment for osteoporosis within last
2 years
- Patient with inflammatory breast cancer
- Prior treatment with anthracyclines at cumulative doses of 450 mg/m² or more for
doxorubicin or 900 mg/m² or more for epirubicin
- Distant metastases of breast cancer beyond regional lymph nodes
- Patient has not recovered from clinical and laboratory acute toxicities of
chemotherapy, radiotherapy and surgery
- Clinically significant, uncontrolled heart disease and/or cardiac repolarization
abnormality, or clinically significant cardiac arrhythmias
- Uncontrolled hypertension with systolic blood pressure >160 mmHg
- Patient is currently receiving any of the prohibited substances that cannot be
discontinued 7 days prior to Cycle 1 Day 1: concomitant medications, herbal
supplements, and/or fruits and their juices that are known as strong inhibitors or
inducers of CYP3A4/5; medications that have a narrow therapeutic window and are
predominantly metabolized through CYP3A4/5; systemic corticosteroids ≤ 2 weeks prior
to starting study drug, or who have not fully recovered from side effects of such
treatment; concomitant medications with a known risk to prolong the QT interval and/or
known to cause torsades de points that cannot be discontinued or replaced by safe
alternative medication.
- Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or
breast-feed during the study
- Women of child-bearing potential unless they are using highly effective methods of
contraception during the study treatment and for 21 days after stopping the study
treatment.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Invasive disease-free survival (iDFS) using STEEP criteria |
Time Frame: | up to 90 months |
Safety Issue: | |
Description: | iDFS is defined as the time from the date of randomization to the date of the first event of local invasive breast recurrence, regional invasive recurrence, distant recurrence, death, contralateral invasive breast cancer, or second primary non-breast invasive cancer, and is assessed locally by investigators. |
Secondary Outcome Measures
Measure: | Recurrence-free survival (RFS) using STEEP criteria |
Time Frame: | up to 90 months |
Safety Issue: | |
Description: | RFS is defined as the time from date of randomization to date of first event of local invasive breast recurrence, regional invasive recurrence, distant recurrence, or death. |
Measure: | Distant disease-free survival (DDFS) using STEEP criteria |
Time Frame: | up to 90 months |
Safety Issue: | |
Description: | DDFS is defined as the time from date of randomization to date of first event of distant recurrence, death, or second primary non-breast invasive cancer |
Measure: | Overall survival (OS) |
Time Frame: | up to 90 months |
Safety Issue: | |
Description: | OS is defined as the time from date of randomization to date of death due to any cause. |
Measure: | Quality of Life (QOL) |
Time Frame: | Baseline, 90 months |
Safety Issue: | |
Description: | Change from baseline in the physical functioning sub-scale score and global health status/QOL scale score as assessed by EORTC QLQ-C30 |
Details
Phase: | Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Withdrawn |
Lead Sponsor: | Novartis Pharmaceuticals |
Trial Keywords
- Hormone receptor-positive
- Estrogen and/or progesterone receptor-positive
- HER2-negative
- Intermediate risk early breast cancer
- Adjuvant
- Ribociclib
- LEE011
- CDK4/6 inhibitor
- Endocrine therapy
- Phase III
- breast carcinoma
- breast cancer
Last Updated
March 15, 2018